Featured Research

from universities, journals, and other organizations

Half of UK patients needing emergency gut exam still face 'serious' delays

Date:
March 31, 2010
Source:
BMJ-British Medical Journal
Summary:
Over half of patients who need emergency investigation of sudden bleeding from their gut are still facing potentially "serious" delays, finds an audit of endoscopy services across the UK.

Over half of patients who need emergency investigation of sudden bleeding from their gut are still facing potentially "serious" delays, finds an audit of endoscopy services across the UK.

Endoscopy involves passing a camera on the end of a flexible tube down the gullet into the stomach. It is a recommended procedure for this type of bleed, known as acute upper gastrointestinal bleeding or AUGIB.

AUGIB is a common medical emergency, usually caused by bleeding from ulcers in the stomach or from veins (variceal bleeds) in the gullet (oesophagus).

It is thought to affect between 50 to150 people in every 100,000 of the population, and results in an annual death toll of 4000 in the UK. Timely endoscopy can therefore save lives, say the authors.

The research team monitored 208 hospitals out of 257 across the UK that admit adult patients with AUGIB for a period of two months in the summer of 2007.

During this period, the records of 6750 patients were checked, three quarters of whom underwent endoscopy while in hospital.

Of these, half took place within the recommended 24 hours of admission, with more than 8 out of 10 investigations carried out during normal working hours. But about 17% took place outside normal working hours (out of hours) including 3% between midnight and 0800 hours.

But of those patients deemed to be at high risk of dying, as assessed by a validated (Rockall) risk score of 5 or more, only just over half (55%) were endoscoped within 24 hours. And 14% of them waited 72 or more hours for the procedure.

Endoscopy revealed that almost a third of patients (28%) were bleeding from conditions that carry a high risk of further bleeding. Three out of four of these patients were endoscoped again. Further bleeding occurred in 13%, over half of whom (7.4%) died.

About half of hospitals (52%) had an organised out of hours endoscopy service, often provided by a specialist, the audit showed. But this figure has scarcely risen since 2005, say the authors.

Hospitals without this type of service depend on the availability and goodwill of specialists who are not on call. One in five initial endoscopies were performed out of hours in hospitals with this service compared with only 13% among those without.

Standard endoscopic therapy, which curbs the risk of re-bleeds and surgery, was also underused, the audit showed. Just over three out of four patients with visible or bleeding blood vessels were given appropriate treatment at endoscopy.

The overall findings are similar to those of a previous audit in 1993, which involved only four regions in England, say the authors.

"This figure [for endoscopy] has not increased since the 1993 audit, even though it is prominently recommended in the [British Society for Gastroenterology] guidelines and those of other organisations," they comment.

"Use of endoscopic therapy for high risk lesions has also increased little since 1993," they add, pointing to the doubling in prevalence of bleeding from gullet veins -- an indication of the increasing numbers of patients with advanced alcoholic liver disease -- between 1993 and 2007.

They note that the numbers of patients needing surgery and dying as a result of AUGIB have fallen, but nevertheless conclude: "This audit has identified serious deficiencies in the use of endoscopy for AUGIB in the UK."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "Half of UK patients needing emergency gut exam still face 'serious' delays." ScienceDaily. ScienceDaily, 31 March 2010. <www.sciencedaily.com/releases/2010/03/100331201537.htm>.
BMJ-British Medical Journal. (2010, March 31). Half of UK patients needing emergency gut exam still face 'serious' delays. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/03/100331201537.htm
BMJ-British Medical Journal. "Half of UK patients needing emergency gut exam still face 'serious' delays." ScienceDaily. www.sciencedaily.com/releases/2010/03/100331201537.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins